Celcuity (CELC) to Release Earnings on Wednesday

Celcuity (NASDAQ:CELC) is scheduled to be announcing its earnings results after the market closes on Wednesday, August 14th. Analysts expect the company to announce earnings of ($0.71) per share for the quarter. Individual that are interested in registering for the company’s earnings conference call can do so using this link.

Celcuity (NASDAQ:CELC) last issued its earnings results on Wednesday, May 15th. The company reported ($0.64) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.07. On average, analysts expect Celcuity to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Celcuity Price Performance

CELC stock opened at $15.06 on Tuesday. The company has a fifty day moving average price of $16.54 and a 200-day moving average price of $16.81. Celcuity has a 52-week low of $8.39 and a 52-week high of $22.19. The company has a market capitalization of $528.62 million, a P/E ratio of -5.42 and a beta of 0.81. The company has a debt-to-equity ratio of 0.28, a quick ratio of 11.23 and a current ratio of 11.23.

Analysts Set New Price Targets

A number of research firms recently commented on CELC. Leerink Partnrs raised Celcuity to a “strong-buy” rating in a research report on Monday, July 22nd. HC Wainwright restated a “buy” rating and set a $27.00 price objective on shares of Celcuity in a research report on Thursday, May 16th. Craig Hallum reissued a “buy” rating and set a $27.00 price target (up from $25.00) on shares of Celcuity in a research note on Thursday, May 16th. SVB Leerink initiated coverage on Celcuity in a research note on Monday, July 22nd. They issued an “outperform” rating and a $29.00 price target on the stock. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a $40.00 price objective on shares of Celcuity in a research note on Thursday, May 16th. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $29.20.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.